Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition
Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye
Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye
View: Text | PDF
Research Article Cell biology Oncology

Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition

  • Text
  • PDF
Abstract

Anoikis resistance, or evasion of cell death triggered by matrix detachment, is a hallmark of cancer cell survival and metastasis. We showed that repeated exposure to suspension stress followed by recovery under attached conditions leads to development of anoikis resistance. The acquisition of anoikis resistance was associated with enhanced invasion, chemoresistance, and immune evasion in vitro and distant metastasis in vivo. This acquired anoikis resistance was not genetic, persisting for a finite duration without detachment stress, but was sensitive to CDK8/19 mediator kinase inhibition that could also reverse anoikis resistance. Transcriptomic analysis revealed that CDK8/19 kinase inhibition induces bidirectional transcriptional changes in both sensitive and resistant cells, disrupting the balanced reprogramming required for anoikis adaptation and resistance by reversing some resistance-associated pathways and enhancing others. Both anoikis resistance and in vivo metastatic growth of ovarian cancers are sensitive to CDK8/19 inhibition, thereby providing a therapeutic opportunity to both prevent and suppress ovarian cancer metastasis.

Authors

Mehri Monavarian, Resha Rajkarnikar, Emily Faith Page, Asha Kumari, Liz Quintero Macias, Felipe Massicano, Nam Y. Lee, Sarthak Sahoo, Nadine Hempel, Mohit Kumar Jolly, Lara Ianov, Elizabeth Worthey, Abhyudai Singh, Igor B. Roninson, Eugenia V. Broude, Mengqian Chen, Karthikeyan Mythreye

×

Figure 8

CDK8/19 inhibition induces bidirectional transcriptional reprogramming in anoikis-sensitive and -resistant cells.

Options: View larger image (or click on image) Download as PowerPoint
CDK8/19 inhibition induces bidirectional transcriptional reprogramming i...
(A) Schematic of RNA-seq design; OV90 AnS and AnR cells treated with DMSO or SNX631 for 4 days in 2D; AnR cells further cultured in suspension ± SNX631. (B) Principal component analysis (PCA) of AnS vs. AnR transcriptomic profiles in 2D (top) and AnR cells in 2D vs. suspension (bottom). (C) UpSet plot of SNX631-regulated DEGs (FDR < 0.01, FC > 1.5) across 3 comparisons: AnS in 2D (AnS-SNX vs. AnS-Ctrl), AnR in 2D (AnR-SNX vs. AnR-Ctrl), and AnR in suspension (AnR-SS vs. AnR-DD). (D) Heatmap of all SNX631-regulated DEGs; columns 1–3: SNX631 response; column 4 (AnR-Ctrl vs. AnS-Ctrl): anoikis resistance-associated DEGs; column 5: acute anoikis response DEGs (AnR-DD vs. AnR-Ctrl). (E and F) Expression (transcripts per million) of representative DEGs upregulated (E) or downregulated (F) by CDK8/19 inhibition in AnR cells in suspension (AnR-SS vs. AnR-DD). (G and H) Expression of genes showing bidirectional regulation: reversed (G) or enhanced (H) by CDK8/19 inhibition. (I) GSVA heatmap of hallmark pathway NES clustered by Euclidean distance. (J) Expression of representative MYC targets V1 and PI3K/AKT/mTOR pathway genes.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts